Whole-body integral dose and post-radiotherapy lymphocytopaenia in solid tumours
- PMID: 40046832
- PMCID: PMC11880780
- DOI: 10.1136/bmjonc-2024-000522
Whole-body integral dose and post-radiotherapy lymphocytopaenia in solid tumours
Abstract
Objective: Since modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) pivot on a strategy of dose redistribution, it may increase integral dose and consequently worsening of lymphocytopaenia. In this study, our objective was twofold: first to validate the correlation between integral body dose and post-treatment lymphocytopaenia in a cohort of patients treated with curative-intent radiotherapy and second to validate its prognostic impact.
Methods and analysis: Patients treated with curative intent radiotherapy with complete blood counts were included in the study. Data on the following variables were collected: treatment site, prescribed dose, use of concurrent chemotherapy, mean body dose, mean body volume, treatment technique and disease-free survival.
Results: A total of 116 patients were included for analysis. There was a significant decline in lymphocyte counts after radiotherapy (2.2×109/L vs 0.8×109/L; p<0.001). Multivariate linear regression analysis of post-treatment lymphocytopaenia revealed a significant correlation with pretreatment lymphocyte counts, integral body dose, use of IMRT and use of concurrent radiosensitising chemotherapy. Univariate survival analysis was performed in 37 patients with squamous cell carcinoma of the head and neck. In the Cox proportional hazards model, post-treatment lymphocyte count was statistically significant as a continuous variable (Hazard Ratio=0.998, p=0.01) and as a dichotomous variable.
Conclusion: The negative correlation between integral body dose and post-treatment lymphocytopaenia was validated, and post-treatment lymphocytopaenia is an adverse prognostic factor in patients with head and neck cancer treated with curative-intent radiotherapy.
Keywords: Biomarkers; Immunocompetence; Lymphocytes; Radiotherapy.
Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
AC: Editor-in-Chief of BMJ Oncology.
Figures
Comment in
-
Does radiation-induced lymphocytopenia matter? Developing a radiotherapy dosimetric strategy for immune preservation and improved survival.BMJ Oncol. 2025 Mar 24;4(1):e000745. doi: 10.1136/bmjonc-2025-000745. eCollection 2025. BMJ Oncol. 2025. PMID: 40135242 Free PMC article. No abstract available.
References
-
- Yovino S, Kleinberg L, Grossman SA, et al. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 2013;31:140–4. doi: 10.3109/07357907.2012.762780. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources